Trial · NCT04773353
Registered outcomes55
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 55
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Circulating concentrations of progesterone | On stimulation day 6 | Blood samples for analysis of circulating concentrations of progesterone will be drawn. |
| Secondary | Circulating concentrations of inhibin A and inhibin B | On stimulation day 6 | Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn. |
| Secondary | Circulating concentrations of FSH and LH | At end-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of FSH and LH will be drawn. |
| Secondary | Circulating concentrations of estradiol | At end-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of estradiol will be drawn. |
| Secondary | Circulating concentrations of progesterone | At end-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of progesterone will be drawn. |
| Secondary | Circulating concentrations of inhibin A and inhibin B | At end-of-stimulation (up to 20 stimulation days) | Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn. |
| Secondary | Total gonadotropin dose | At end-of-stimulation (up to 20 stimulation days) | The total gonadotropin dose will be recorded. |
| Secondary | Number of stimulation days | At end-of-stimulation (up to 20 stimulation days) | |
| Secondary | Proportion of subjects with investigator-requested gonadotropin dose adjustments | From stimulation Day 6 to end-of-stimulation (up to 20 stimulation days) | The decreases and increases of the gonadotropin dose will be captured during the stimulation period. |
| Secondary | Number of events and intensity of adverse events | From signing of the informed consent up to end-of-trial (approximately 5.5 months) | |
| Secondary | Changes from baseline in circulating levels of clinical chemistry parameters: Albumin and Total protein | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical chemistry parameters including: Albumin and Total protein. |
| Secondary | Changes from baseline in circulating levels of clinical chemistry parameters: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase, Gamma-glutamyl transpeptidase | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical chemistry parameters including: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase and Gamma-glutamyl transpeptidase. |
| Secondary | Changes from baseline in circulating levels of clinical chemistry parameters: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium, Uric acid | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical chemistry parameters including: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium and Uric acid. |
| Secondary | Changes from baseline in circulating levels of clinical chemistry parameters: Bilirubin direct, Bilirubin, Creatinine | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical chemistry parameters including: Bilirubin direct, Bilirubin and Creatinine. |
| Secondary | Changes from baseline in circulating levels of clinical chemistry parameters: Lactate dehydrogenase | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical chemistry parameter including: Lactate dehydrogenase. |
| Secondary | Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-stimulation | At end-of-stimulation (up to 20 stimulation days) | Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid. |
| Secondary | Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-trial | At end-of-trial (up to approximately 5.5 months) | Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid. |
| Secondary | Changes from baseline in circulating levels of clinical haematology parameters: Red blood cells, Red blood cells morphology | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical haematology including: Red blood cells and Red blood cell morphology. |
| Secondary | Changes from baseline in circulating levels of clinical haematology parameters: White blood cells, White blood cell morphology, Platelets | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical haematology including: White blood cells, White blood cell morphology and Platelets. |
| Secondary | Changes from baseline in circulating levels of clinical haematology parameters: Haemoglobin | From screening up to end-of-trial (up to approximately 5.5 months) | Blood samples will be collected for the analysis of clinical haematology parameter including: Haemoglobin. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04773353/registered?page=2